CJC-1295 is a 30-residue GHRH analog available in two research forms — with DAC (long-acting, albumin-binding) and no-DAC (short, pulsatile Mod GRF 1-29). This is the full New Zealand research reference: structure, PK, blending logic, reconstitution and COA checklist.
The CJC-1295 peptide is a 30-residue analog of endogenous growth-hormone-releasing hormone (GHRH 1-29) engineered with four amino-acid substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) that confer resistance to enzymatic cleavage. In the published literature the CJC-1295 peptide is documented in two research forms — with a Drug Affinity Complex (DAC) maleimide linker for covalent albumin binding, and without DAC (also called Mod GRF 1-29). The two forms share the same core GHRH sequence but differ dramatically in pharmacokinetics, which drives every downstream research-design choice.
For New Zealand laboratories referencing the CJC-1295 peptide alongside GHSR agonists such as ipamorelin, the DAC vs no-DAC decision is the single most important variable to record on the batch worksheet. This Kiwi Peps research profile summarises structure, PK, reconstitution and analytical documentation expectations for the CJC-1295 peptide.
CJC-1295 peptide structure at a glance
| Attribute | Specification |
|---|---|
| Sequence length | 30 residues (GHRH 1-29 analog + DAC site on Cys³⁰ for the DAC form) |
| Molecular weight (DAC) | ≈ 3,367 Da |
| Molecular weight (no-DAC) | ≈ 3,367 Da (Mod GRF 1-29, no linker) |
| Key substitutions | D-Ala², Gln⁸, Ala¹⁵, Leu²⁷ |
| Receptor target | GHRH receptor (GHRHR) on pituitary somatotrophs |
| Documented purity spec | ≥ 98% by HPLC |
DAC vs no-DAC pharmacokinetics
| Parameter | CJC-1295 with DAC | CJC-1295 no-DAC (Mod GRF 1-29) |
|---|---|---|
| Half-life (published) | ~6–8 days | ~30 minutes |
| GH release pattern | Sustained bleed | Pulsatile, mimics native GHRH |
| Reference dosing frequency | Weekly | Multiple pulses per day |
| Common research pairing | Rarely combined with GHSR agonists | Frequently paired with ipamorelin |
| PK modelling use | Steady-state exposure studies | Pulse-amplitude and IGF-1 kinetics |
Why researchers reference the CJC-1295 peptide
- Well-characterised GHRH receptor engagement with reproducible PK profiles.
- Two forms allow parallel study designs — sustained vs pulsatile GH kinetics.
- Established as a benchmark comparator against sermorelin and tesamorelin.
- Extensive published data on synergy with GHSR agonists (ipamorelin, GHRP-2, GHRP-6).
Reconstitution reference (research use only)
| Vial size | Diluent (BAC water) | Concentration |
|---|---|---|
| 2 mg | 2 mL | 1000 mcg/mL |
| 5 mg | 2.5 mL | 2000 mcg/mL |
| 5 mg | 5 mL | 1000 mcg/mL |
- Batch identifier and synthesis date traceable to the lot record
- HPLC purity ≥98% (typically ≥99% for peptides under 30 residues)
- LC-MS confirmed monoisotopic or average mass within ±0.5 Da of theoretical
- Counterion identity and content (acetate or trifluoroacetate) reported
- Bacterial endotoxin and residual solvents per the analytical method
CJC-1295 peptide FAQ
What is the CJC-1295 peptide?
The CJC-1295 peptide is a 30-residue GHRH analog with substitutions that resist enzymatic degradation, available in DAC (long-acting) and no-DAC (short-acting) research forms.
What is the difference between CJC-1295 DAC and no-DAC?
DAC adds a maleimide linker that covalently binds serum albumin, extending half-life into the multi-day range. No-DAC (Mod GRF 1-29) has a ~30-minute half-life that preserves pulsatile GH kinetics.
Is CJC-1295 the same as Mod GRF 1-29?
Mod GRF 1-29 is the no-DAC form of CJC-1295 — the same GHRH backbone without the DAC linker.
Why is CJC-1295 paired with ipamorelin?
CJC-1295 acts on the GHRH axis while ipamorelin acts on the GHSR (ghrelin) axis. The two independent mechanisms are documented together in published GH-axis literature as a canonical synergy pair.
Where can New Zealand researchers buy the CJC-1295 peptide?
Kiwi Peps supplies research-grade CJC-1295 (DAC and no-DAC) at ≥98% HPLC purity with third-party COA and same-day domestic dispatch. Strictly research use only.
